6,016 followers
RT @crd_york: Latest paper from CRD/CHE Evidence Review Group: Brodalumab for the treatment of moderate-to-severe plaque psoriasis: an Evid…
RT @crd_york: Latest paper from CRD/CHE Evidence Review Group: Brodalumab for the treatment of moderate-to-severe plaque psoriasis: an Evid…
RT @crd_york: Latest paper from CRD/CHE Evidence Review Group: Brodalumab for the treatment of moderate-to-severe plaque psoriasis: an Evid…
Latest paper from CRD/CHE Evidence Review Group: Brodalumab for the treatment of moderate-to-severe plaque psoriasis: an Evidence Review Group evaluation of a NICE Single Technology Appraisal https://t.co/10ySIQEHa1 @CHEyork #brodalumab #psoriasis
#HealthEconJA Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal https://t.co/GqrUF2jBRf